The Food and Drug Administration granted marketing approval to AstraZeneca’s gout medicine Zurampic. Zurampic was approved as combination therapy with a xanthine oxidase inhibitors (XOIs) for the treatment of hyperuricemia — an excess of uric acid in the blood — associated with gout in patients who have responded to XOIs alone.
Private equity firm TPG Growth just invested $75 million in Precision for Medicine, a Maryland-based startup that melds value-based care with precision medicine.
We’re waiting to hear back from TPG Growth and Precision for Medicine for comment on how this funding will be deployed.
Global biopharmaceutical business AstraZeneca has expanded its presence in Asia by entering two significant relationships with medical companies in China and Japan.
A strategic alliance was announced on December 16, between WuXi AppTec (WuXi), an open-access research and development capability and technology platform company, and, MedImmune, the global biologics research and development arm of AstraZeneca.
Today, the White House announced the latest recipients of the National Medal of Science and National Medal of Technology and Innovation—our Nation’s highest honors for achievement and leadership in advancing the fields of science and technology. The new awardees will receive their medals at a White House ceremony early next year.
NHLBI has issued the first in a series of Requests for Information (RFIs) to solicit input from its stakeholders on ways to optimize the clinical trials enterprise. This first RFI seeks stakeholder views on clinical trial management, performance milestones, and metrics.
NHLBI has an important legacy of conducting and funding clinical trials that have provided critical insights into mechanisms of human disease and have shaped medical practice improving the lives of those with sickle cell disease, chronic obstructive pulmonary disease, cardiovascular disease, and other debilitating conditions. In funding and overseeing these trials, NHLBI has an important stewardship responsibility to the research participants and the public.
Venky Ganeson, managing director of Menlo Ventures and future chairman of the National Venture Capital Association, told Inc. that 2015 has been the third-strongest year for venture capital investment since the dot-com bubble of the late 1990s. Only 1999 and 2000 were stronger years. The LA Times reported there was $98 billion in worldwide venture capital investment in the first three quarters of 2015 alone. That’s 11 percent higher than the investments for all of 2014.
When the Centers for Medicare & Medicaid Services (CMS) issued their 2014 quality and financial performance results in August, an accountable care organization (ACO) formed by Johns Hopkins achieved a perfect score for quality reporting.
The Johns Hopkins Medicine Alliance for Patients, or “JMAP,” reported on all 33 quality measures. A perfect quality reporting score is an indication that the ACO is able to provide timely, complete and appropriate information to CMS regarding each of the requisite ACO quality measures.
OrbiMed, a leading investment firm focused on the healthcare sector, announced the closing of its next venture capital fund, OrbiMed Private Investments VI, LP, with $950 million in limited partner commitments. Investors in the fund include some of the preeminent medical research institutions globally, along with leading endowments, foundations and sovereign wealth funds.
It’s taken 30 years and more than $565 million to make it happen: the first-ever malaria vaccine. The innoculation, called Mosquirix, is the first of its kind to fight a parasite and has the potential to transform the lives of millions of people living in malaria-stricken areas. An estimated half million people die from the disease every year, the majority children. Such deaths have fallen by 47% since 2000 thanks to better prevention methods, but many have been waiting a long time for a vaccine that could protect children better and earlier.
Headquartered in Pasadena, California, Alexandria Real Estate Equities (ARE) was founded by Joel S. Marcus and Jerry M. Sudarsky in 1994. The company is structured as a REIT (real estate investment trust) and completed an initial public offering in 1997. The company is now the third-largest publicly traded office REIT in the United States and is part of the S&P 400.
